Health

111 Signs Strategic Cooperation Agreement with Jianming Pharmaceutical to Develop Chronic Disease Management Platform

SHANGHAI, March 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (Nasdaq: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, and Jianming Pharmaceutical Group ("Jianming Pharmaceutical"), a p...

2021-03-25 17:00 2440

GenScript Signs a Strategic Partnership with the Theragen Etex and MedPACTO for Therapeutic Antibody Drug development

SINGAPORE, March 25, 2021 /PRNewswire/ -- A global leading biotech company GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) announced that the Company has entered into a strategic partnership with the Theragen Etex, a South Korea-based comprehensive pharmaceutical and biotechnology...

2021-03-25 16:35 4130

Nippon Express Obtains IATA CEIV Pharma Certification for Temperature-controlled Facility near Narita Airport

TOKYO, March 25, 2021 /PRNewswire/ -- Nippon Express Co., Ltd. has obtained IATA CEIV Pharma (*) pharmaceutical transport quality certification for its Narita Temperature-Controlled Hub (NTCH) and for transport operations between NTCH and Narita Airport, effectiveMarch 15. This is the second pha...

2021-03-25 15:00 2304

No COVID slump as majority of Australians satisfied with healthcare system new Australian Healthcare Index reports

MELBOURNE and PERTH, Australia, March 25, 2021 /PRNewswire/ -- Despite a once-in-a-century pandemic still lingering one year on, Australians have given a vote of confidence to the Australian healthcare system with 65.5% rating it a score of 8 or above out of 10 in a new report, produced by the Au...

2021-03-25 03:00 1762

Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar

TAIPEI, March 24, 2021 /PRNewswire/ -- In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. E...

2021-03-24 23:27 3362

Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies

NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology companydedicated on developing novel cellular immunotherapy for cancer, today announced that it had secured $80 million in Series B Financing. The Series B was co-led by GL Ventures, the ven...

2021-03-24 22:01 20873

Ping An and Zhongshan Hospital to Collaborate on "Healthcare + Finance + Technology" Innovations

HONG KONG and SHANGHAI, March 24, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company ofChina, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) has signed a strategic cooperation agreement with Zhongshan Hospital, which is affiliated with Fudan University inShanghai. The two ...

2021-03-24 20:15 5760

Fishawack Health unveils an unrivaled global market access and HEOR offering with the acquisition of PRMA Consulting

Fishawack Health bolsters its strong strategic offering by acquiring PRMA Consulting – a global market access and HEOR consulting leader with significant  expertise in US, EU, and Asia-Pacific markets LONDON, March 24, 2021 /PRNewswire/ -- Leading life science commercialization partnerFishawack H...

2021-03-24 20:00 1977

Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation

SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Ev...

2021-03-24 19:07 1920

LimaCorporate And HSS Partner To Open First Provider-based Design And 3D Printing Center For Complex Joint Reconstruction Surgery

SAN DANIELE DEL FRIULI, Italy, March 24, 2021 /PRNewswire/ -- LimaCorporate  S.p.A., (Lima) leading global orthopedics manufacturer, andHospital for Special Surgery (HSS), top-ranked in orthopedics for 11 consecutive years in the U.S., byU.S. New...

2021-03-24 16:00 2070

Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

* Over 22,000 participants aged 18 years or older are expected to be enrolled in SPECTRA acrossLatin America, Asia, Europe and Africa * Interim analysis of the primary endpoint expected in the middle of 2021 CHENGDU, China and EMERYVILLE, Calif., March 24, 2021 /PRNewswire/ -- Clover Biopharm...

2021-03-24 14:18 3187

Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson's disease with the US FDA

HONG KONG, March 23, 2021 /PRNewswire/ -- Forest Hills Partners Hong Kong Limited (also known as Forest Hills Lab) is ready to file an Investigative New Drug (IND) application with the US FDA inApril 2021 to assess tolerability and efficacy with one of its drug candidates, namely FHL-301 in a pha...

2021-03-24 12:25 5274

Mindray Releases New Ceiling Supply Unit, Creating a More Optimized ICU Environment

SHENZHEN, China, March 24, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global leader in developing and providing medical devices, has released a new series of ceiling supply units which exceeds ISO 11197-2019 standards. The HyPort R80 is the newest generation of bedside device management syste...

2021-03-24 11:49 1994

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients

* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy * GAVRETO is the first approved selective RET inhibitor in China and first approved precision therapy for CStone SUZHOU,...

2021-03-24 10:46 5047

Transcenta Announces Appointments of Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK and Translational Science

SUZHOU, China, March 23, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), aclinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the expansion of its senior managem...

2021-03-24 08:00 1363

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. BAGSVÆRD, Denmark, March 24, 2021 /PRNewswire/ -- New results from the STEP phase 3a clinical trial p...

2021-03-24 04:41 1440

Dr. Cheng-Chi Chao joins ChemPartner as Vice President and Head of Immunotherapy and Inflammation

SHANGHAI, March 23, 2021 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment of Cheng-Chi Chao, Ph.D. as Vice President and Head of Immunotherapy and Inflammation. Dr. Chao has over 20 years of experience in drug development and extensive expertise in the fields of immune-oncolo...

2021-03-24 00:02 2357

Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights

SUZHOU, China, March 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), reported financial results for the full year ended December 31, 2020 and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "2020 is amilestone ...

2021-03-23 23:08 4287

2020 Results Record High Despite a Challenging Year

Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million Net Profit Grew by 67.5% Y-o-Y to RMB1,693 Million Record-high Gross Margin of 45.1% and Net Profit Margin of 30.2% Milestone Revenue Surged by 71.7% to US$95 Million Total Backlog up 122.0% to ...

2021-03-23 20:59 4003

RDIF: Sputnik V approved in Vietnam

MOSCOW, March 23, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of the Socialist Republic ofVietnam. Thus Sputnik V is now approved for use in 56...

2021-03-23 20:45 2484
1 ... 639640641642643644645 ... 858